Capricor Therapeutics, Inc.
Capricor Therapeutics is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for muscular and other diseases. Their lead candidate, deramiocel (CAP-1002), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company also develops exosome technology as a next-generation therapeutic platform, aiming to deliver nucleic acids and proteins to treat or prevent various diseases. They are engaged in clinical trials, regulatory updates, and have a pipeline of innovative therapies.
Industries
Nr. of Employees
small (1-50)
Capricor Therapeutics, Inc.
Los Angeles, California, United States, North America
Products
Allogeneic cardiosphere-derived cell therapy candidate
An allogeneic cell therapy candidate derived from cardiosphere-derived cells, developed for treatment of Duchenne muscular dystrophy and advanced into late-stage clinical evaluation.
Engineered exosome therapeutic platform
A development platform focusing on engineered exosomes intended to deliver defined nucleic acids and proteins for therapeutic applications across multiple indications.
Allogeneic cardiosphere-derived cell therapy candidate
An allogeneic cell therapy candidate derived from cardiosphere-derived cells, developed for treatment of Duchenne muscular dystrophy and advanced into late-stage clinical evaluation.
Engineered exosome therapeutic platform
A development platform focusing on engineered exosomes intended to deliver defined nucleic acids and proteins for therapeutic applications across multiple indications.
Services
Collaborative research and development partnerships
Partnerships with external organizations for co-development of cell- and exosome-based therapeutics, including shared preclinical and clinical programs.
Expanded access program coordination
Policy-driven program coordination to evaluate and manage expanded access / compassionate use requests in accordance with an established company policy.
Collaborative research and development partnerships
Partnerships with external organizations for co-development of cell- and exosome-based therapeutics, including shared preclinical and clinical programs.
Expanded access program coordination
Policy-driven program coordination to evaluate and manage expanded access / compassionate use requests in accordance with an established company policy.
Expertise Areas
- Cell therapy development (allogeneic)
- Exosome and extracellular vesicle therapeutics
- Clinical trial design and management
- CMC and biologics manufacturing scale-up
Key Technologies
- Exosome / extracellular vesicle engineering
- Allogeneic cell therapy (cardiosphere-derived cells)
- Nucleic acid and protein delivery via extracellular vesicles
- Biologics manufacturing and CMC processes